APTO-253
253-HEM1-01
Phase 1 small_molecule terminated
Quick answer
APTO-253 for Acute Myelogenous Leukemia in Relapse is a Phase 1 program (small_molecule) at Aptose Biosciences with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Aptose Biosciences
- Indication
- Acute Myelogenous Leukemia in Relapse
- Phase
- Phase 1
- Modality
- small_molecule
- Status
- terminated